{"id":"jw0104-c2403","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a combination of JW0104 (an investigational immunotherapeutic) and C2403 (an investigational agent from JW Pharmaceutical). The exact molecular mechanisms are not publicly detailed, but the combination approach in phase 3 suggests synergistic immunomodulatory or checkpoint-related activity. Specific target details remain proprietary.","oneSentence":"JW0104+C2403 is a combination therapy designed to enhance anti-tumor immunity through dual mechanism targeting.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:39.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oncology indication (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT06643130","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia","status":"RECRUITING","sponsor":"JW Pharmaceutical","startDate":"2024-12-02","conditions":"Hypertension, Dyslipidemia","enrollment":162}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NA (Not Applicable)"],"phase":"phase_3","status":"active","brandName":"JW0104+C2403","genericName":"JW0104+C2403","companyName":"JW Pharmaceutical","companyId":"jw-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JW0104+C2403 is being studied in a clinical trial for its efficacy and safety in treating patients with hypertension and dyslipidemia. The trial is a multi-center, randomized, double-blind, parallel, Phase Ⅲ clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}